Sagimet Biosciences (SGMT) stock was rated with a buy rating and $12 price target at UBS due to its propects against liver disease MASH. Read more here.
UBS last night upgraded 3M (MMM ... If successful, 3M’s earnings per share can eclipse $10 by 2028, or 40% above 2024 levels, while the stock’s valuation remains at a discount, the analyst tells ...
In addition to UBS, RWE AG also received a Buy from RBC Capital’s Alexander ... Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock.